Related Experiment Video
Updated: Oct 11, 2026

Amikacin Protection Assay for Quantification and Visualization of Escherichia coli Cell Invasion
Published on: July 3, 2026
Indole decreases the virulence of enterotoxigenic Escherichia coli
Sofia Razzaq Meo1, Christophe Noppe2, Patrick De Clercq2
1Center for Microbial Ecology and Technology (CMET), Department of Biotechnology, Ghent University, Frieda Saeysstraat 1, Ghent, 9052, Belgium.
Abstract:
Indole signaling is being explored as one of the promising targets for anti-virulence therapy against antibiotic-resistant pathogens. Indole has been reported to influence key virulence-related phenotypes, particularly motility and biofilm formation, in various bacterial pathogens. This study aimed to investigate the impact of indole on enterotoxigenic Escherichia coli (ETEC). The results revealed that indole decreased both swimming motility and biofilm formation in ETEC across concentrations ranging from 0 to 1000 µM, with a maximum reduction of 75% in swimming motility and 47% in biofilm formation at the highest concentration. RT-qPCR analysis revealed that motility-related genes (i.e., flagellin fliC and flagellar transcription activator flhC) were downregulated by 5-fold and 2.5-fold, respectively. Additionally, the stress response sigma factor gene rpoS and the heat-stable enterotoxin gene estP were downregulated by 2-fold and 1.7-fold, respectively. Competitive ELISA showed that indole decreased secreted heat-stable enterotoxin levels by more than 10-fold, which is consistent with the decreased estP mRNA levels. Finally, indole decreased the virulence of ETEC towards the invertebrate infection model Galleria mellonella, resulting in a 1.8-fold increased survival after 5 days. These findings indicate that indole signaling controls ETEC virulence, making it an interesting target for anti-virulence therapy.
Related Concept Videos
Bacterial Gastroenteritis
Cholera
Bacterial Toxins
Regulation of Bacterial Virulence
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
